natgillin/translations-raw huggingface dataset:
Only use needles that are compatible for use with SoloStar.
Koristiti samo igle koje su prikladne za uporabu s brizgalicom SoloStar.
Switch from other insulins to Lantus
Prijelaz s drugih inzulina na Lantus
EU/1/00/134/030 1 pen of 3 ml.
EU/1/00/134/001 1 bočica od 5 ml
Lantus in cartridges is only suitable for injecting just under the skin using a reusable pen (see also section 3).
Lantus u ulošcima je prikladan samo za ubrizgavanje neposredno pod kožu pomoću brizgalice za višekratnu uporabu (također vidjeti dio 3).
How to use Lantus
Kako primjenjivati Lantus
Correspondingly, the incidences of nocturnal hypoglycaemia were 32% in the insulin glargine / lispro group versus 52% in the NPH / regular group.
32% u skupini koja je primala inzulin glargin/lispro, naspram 52% u skupini koja je primala
Subcutaneous use Use specific pens: see leaflet.
Koristiti odgovarajuće brizgalice: vidjeti uputu.
Lantus in pre-filled pen is only suitable for injecting just under the skin (see also section 3).
Lantus u napunjenoj brizgalici je prikladan samo za ubrizgavanje neposredno pod kožu (također vidjeti dio 3).
You must always check the insulin label before each injection to avoid mix-ups between Lantus and other insulins.
Prije svake injekcije morate provjeriti naljepnicu na inzulinu kako bi se izbjegla zamjena lijeka Lantus i drugih inzulina.
Rare reported side effect (may affect up to 1 in 1,000 people)
Rijetko prijavljene nuspojave (mogu se javiti u manje od 1 na 1000 osoba)
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with Lantus is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of Lantus.
Farmakokinetički i farmakodinamički nalazi pokazuju da se učinak supkutane injekcije lijeka Lantus uglavnom temelji na izloženosti metabolitu M1. U najvećeg broja ispitanika inzulin glargin i metabolit
It should be handled with care.
Rukujte njime oprezno.
If administration by syringe is necessary, a vial should be used (see section 4.2 and 4.4).
. Ako je potrebna primjena pomoću štrcaljke, potrebno je koristiti bočicu (vidjeti dijelove 4.2 i 4.4).
Medicines that may cause your blood sugar level to fall (hypoglycaemia) include: - all other medicines to treat diabetes, - angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure), - disopyramide (used to treat certain heart conditions), - fluoxetine (used to treat depression), - fibrates (used to lower high levels of blood lipids), - monoamine oxidase (MAO) inhibitors (used to treat depression), - pentoxifylline, propoxyphene, salicylates (such as acetylsalicylic acid, used to relieve pain and lower fever), - sulfonamide antibiotics.
Lijekovi koji mogu uzrokovati pad razine šećera u krvi (hipoglikemiju) obuhvaćaju: - sve druge lijekove za liječenje šećerne bolesti, - inhibitore angiotenzin konvertirajućeg enzima (ACE-inhibitore) (koriste se za liječenje nekih srčanih poremećaja ili visokog krvnog tlaka), - dizopiramid (koristi se za liječenje nekih srčanih bolesti), - fluoksetin (koristi se za liječenje depresije), - fibrate (koriste se za snižavanje visoke razine masnoća u krvi), - inhibitore monoaminooksidaze (MAO inhibitore) (koriste se za liječenje depresije),
Read carefully the "SoloStar Instructions for Use" included in this package leaflet.
Pažljivo pročitajte „Upute za uporabu brizgalice SoloStar“ koje su sastavni dio ove upute o lijeku.
Lantus 100 units/ml solution for injection in a vial Each vial contains 5 ml of solution for injection, equivalent to 500 units, or 10 ml of solution for injection, equivalent to 1000 units.
Lantus 100 jedinica/ml otopina za injekciju u bočici Jedna bočica sadrži 5 ml otopine za injekciju, što odgovara 500 jedinica, odnosno 10 ml otopine za injekciju, što odgovara 1000 jedinica.
Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins.
Prije svake injekcije uvijek se mora provjeriti naljepnica na inzulinu kako ne bi došlo do medikacijskih pogrešaka zbog zamjene inzulina glargina i drugih inzulina.
Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen Type 1 colourless glass cartridge with a black plunger (bromobutyl rubber) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber) containing 3 ml of solution.
Lantus SoloStar 100 jedinica/ml otopina za injekciju u napunjenoj brizgalici Uložak od bezbojnog stakla tipa 1 s crnim klipom (brombutilna guma) i zatvaračem s rubnikom (aluminij) s čepom (bromobutilna guma ili poliizoprenski laminat i bromobutilna guma) sadrži 3 ml otopine.
Solution for injection 1 cartridge of 3 ml.
Otopina za injekciju 1 uložak od 3 ml.
The Lantus cartridges are to be used only with the pens: ClikSTAR, Tactipen, Autopen 24, AllStar, AllStar PRO, JuniorSTAR.
Lantus ulošci smiju se koristiti samo u kombinaciji s brizgalicama: ClikSTAR, Tactipen, Autopen 24, AllStar, AllStar PRO, JuniorSTAR.
General disorders and administration site conditions Injection site reactions include redness, pain, itching, hives, swelling, or inflammation.
Opći poremećaji i reakcije na mjestu primjene Reakcije na mjestu injiciranja uključuju crvenilo, bol, svrbež, koprivnjaču, oticanje ili upalu.
The insulin may not work very well.
Može se dogoditi da inzulin koji injicirate na tom mjestu ne djeluje dobro.
If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet).
Ako Vam je šećer u krvi prenizak (hipoglikemija), slijedite upute za slučaj hipoglikemije (vidjeti uokvireni tekst na kraju ove upute o lijeku).
D-65926 Frankfurt / Main Germany
D-65926 Frankfurt na Majni
When given intravenously the elimination half-life of insulin glargine and human insulin were comparable.
Kod intravenske primjene, poluvrijeme eliminacije inzulina glargina i ljudskog inzulina bilo je usporedivo.
The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)].
Primarni cilj ispitivanja - dokazati da inzulin glargin nije inferioran u odnosu na NPH u svim slučajevima hipoglikemije - nije postignut, a zabilježen je trend povećanja broja slučajeva hipoglikemije u skupini koja je primala inzulin glargin [omjer inzulin glargin: NPH (95% CI) = 1,18 Varijabilnosti u vrijednostima glikiranog hemoglobina i glukoze bile su usporedive u obje terapijske skupine.
You may need to talk about - the availability of your insulin in the country you are visiting,
Možda ćete morati porazgovarati o: - dostupnosti inzulina u zemlji koju posjećujete,
Opened vials, in-use cartridges or SoloStar pens For storage conditions after first opening of this medicinal product, see section 6.3.
Uvjete čuvanja nakon prvog otvaranja lijeka, vidjeti u dijelu 6.3.
Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will - determine how much Lantus per day you will need and at what time.
Na temelju Vašeg načina života, rezultata pretraga razine šećera (glukoze) u krvi te ranije uporabe inzulina, Vaš liječnik će:
Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg).
Jedan ml sadrži 100 jedinica inzulina glargina* (što odgovara 3,64 mg).
- If you are not eating enough your blood sugar level may become too low (hypoglycaemia).
- Ako ne jedete dovoljno, razina šećera u krvi može postati preniska (hipoglikemija).
Step 3.
PRILOG III.
To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with Lantus should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.
Prijelaz s primjene NPH inzulina dvaput dnevno na Lantus Kako bi se umanjio rizik od noćne i ranojutarnje hipoglikemije, bolesnici koji prelaze s primjene bazalnog NPH inzulina dvaput na dan na Lantus jedanput na dan moraju u prvim tjednima liječenja smanjiti dozu bazalnog inzulina za 20-30%.
After subcutaneous injection of Lantus in diabetic patients, insulin glargine is rapidly metabolized at the carboxyl terminus of the Beta chain with formation of two active metabolites M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin).
Nakon supkutane primjene lijeka Lantus u bolesnika sa šećernom bolešću inzulin glargin se brzo metabolizira na karboksilnim krajevima beta lanca, pri čemu nastaju dva aktivna metabolita: M1
You must check that your insulin pen is working properly before you inject the first dose.
Prije injiciranja prve doze morate provjeriti radi li Vaša inzulinska brizgalica ispravno.
There were no differences between insulin glargine and standard care for the two co-primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.
Nisu primijećene razlike između inzulina glargina i standardnog liječenja za dva primarna ishoda, za bilo koju mjeru koja je sastavnica navedenih ishoda,
EU/1/00/134/031 3 pens of 3 ml EU/1/00/134/032 4 pens of 3 ml EU/1/00/134/033 5 pens of 3 ml EU/1/00/134/034 6 pens of 3 ml EU/1/00/134/035 8 pens of 3 ml EU/1/00/134/036 9 pens of 3 ml EU/1/00/134/037 10 pens of 3 ml
EU/1/00/134/030 1 brizgalica od 3 ml EU/1/00/134/031 3 brizgalice od 3 ml EU/1/00/134/032 4 brizgalice od 3 ml EU/1/00/134/033 5 brizgalica od 3 ml EU/1/00/134/034 6 brizgalica od 3 ml EU/1/00/134/035 8 brizgalica od 3 ml EU/1/00/134/036 9 brizgalica od 3 ml EU/1/00/134/037 10 brizgalica od 3 ml
EU/1/00/134/013 1 cartridge of 3 ml EU/1/00/134/014 3 cartridges of 3 ml EU/1/00/134/005 4 cartridges of 3 ml EU/1/00/134/006 5 cartridges of 3 ml EU/1/00/134/015 6 cartridges of 3 ml EU/1/00/134/016 8 cartridges of 3 ml EU/1/00/134/017 9 cartridges of 3 ml EU/1/00/134/007 10 cartridges of 3 ml
EU/1/00/134/013 1 uložak od 3 ml EU/1/00/134/014 3 uloška od 3 ml EU/1/00/134/005 4 uloška od 3 ml EU/1/00/134/006 5 uložaka od 3 ml EU/1/00/134/015 6 uložaka od 3 ml EU/1/00/134/016 8 uložaka od 3 ml EU/1/00/134/017 9 uložaka od 3 ml EU/1/00/134/007 10 uložaka od 3 ml
Keep the pen protected from light.
Brizgalicu čuvati zaštićenu od svjetlosti.
8 cartridges of 3 ml.
8 uložaka od 3 ml.
Solution for injection 1 vial of 10 ml
Otopina za injekciju 1 bočica od 10 ml
SoloStar is a pre-filled pen for the injection of insulin.
SoloStar je napunjena brizgalica za injiciranje inzulina.
Before using the pre-filled pen, the instructions for use included in the package leaflet must be read carefully.
Prije uporabe brizgalice SoloStar moraju se pažljivo pročitati upute za uporabu koje su sastavni dio upute o lijeku.
Examples include: - you have not injected your insulin or not injected enough, or if it has become less effective,for example through incorrect storage, - your insulin pen does not work properly, - you are doing less exercise than usual, you are under stress (emotional distress, excitement), or you have an injury, operation, infection or fever, - you are taking or have taken certain other medicines (see section 2, "Other medicines and
Primjeri: - ako niste injicirali inzulin ili ako niste injicirali dovoljno inzulina, ili ako je djelotvornost inzulina smanjena, primjerice zbog nepravilnog čuvanja, - ako vježbate manje nego obično, ako ste pod stresom (emocionalno uznemireni ili uzbuđeni) ili ako ste ozlijeđeni ili operirani, imate infekciju ili vrućicu,
Cartridges in use (in the insulin pen) or carried as a spare may be stored for a maximum of 4 weeks not above 30°C and away from direct heat or direct light.
Ulošci u uporabi (u inzulinskoj brizgalici) ili rezervni ulošci mogu se čuvati najdulje 4 tjedna na temperaturi do 30°C, zaštićeni od izvora topline i izravne svjetlosti.
Hypoglycaemia is also more likely to occur if - you have just begun insulin treatment or changed to another insulin preparation (when changing from your previous basal insulin to Lantus hypoglycaemia, if it occurs, may be more likely to occur in the morning than at night), - your blood sugar levels are almost normal or are unstable, - you change the area of skin where you inject insulin (for example from the thigh to the upper arm), - you suffer from severe kidney or liver disease, or some other disease such as hypothyroidism.
Hipoglikemija se također češće može pojaviti: - ako ste upravo započeli liječenje inzulinom ili ste prešli na drugi inzulinski pripravak (kad prelazite s prethodnog bazalnog inzulina na Lantus, hipoglikemija će se, ako se javi, vjerojatnije javljati ujutro nego tijekom noći), - ako Vam je razina šećera u krvi gotovo normalna ili nije stabilna, - ako promijenite područje na koži u koje injicirate inzulin (primjerice s bedra na nadlakticu),
The cartridge in use must not be stored in a refrigerator.
Brizgalica u uporabi ne smije se odlagati u hladnjak.
If administration by syringe is necessary, a vial should be used (see section 4.4).
Ako je potrebna primjena pomoću štrcaljke, potrebno je koristiti bočicu (vidjeti dio 4.4).
SoloStar is a pre-filled disposable pen containing insulin glargine.
SoloStar je napunjena brizgalica za jednokratnu uporabu koja sadrži inzulin glargin.
Lantus in cartridges is only suitable for injecting just under the skin using a reusable pen.
Lantus u ulošcima je prikladan samo za ubrizgavanje neposredno pod kožu pomoću brizgalice za višekratnu uporabu.
In clinical studies, antibodies that cross-react with human insulin and insulin glargine were observed with the same frequency in both NPH-insulin and insulin glargine treatment groups.
U kliničkim je ispitivanjima učestalost križnih reakcija protutijela s ljudskim inzulinom i inzulinom glarginom bila podjednaka u skupinama liječenima NPH inzulinom odnosno inzulinom glarginom.
In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin.
Nakon supkutane injekcije inzulina glargina koncentracije inzulina u serumu zdravih osoba i dijabetičara ukazivale su na sporiju i značajno dulju apsorpciju te na izostanak vršne koncentracije u usporedbi s ljudskim NPH inzulinom.
Your ability to concentrate or react may be reduced if: - you have hypoglycaemia (low blood sugar levels), - you have hyperglycaemia (high blood sugar levels), - you have problems with your sight.
Vaša sposobnost koncentracije i reagiranja može biti oslabljena: - ako imate hipoglikemiju (nisku razinu šećera u krvi),
In use conditions:
Brizgalice u uporabi:
The plunger will reach the end of the cartridge when the total of 300 units of insulin has been used.
Klip će doći do kraja uloška kada se potroši svih
Injection sites must be rotated within a given injection area from one injection to the next.
Mjesto injiciranja mora se promijeniti kod svake injekcije unutar preporučenog područja davanja.
- If you have missed a dose of Lantus or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia).
Ako ste zaboravili primijeniti Lantus - Ako ste propustili dozu lijeka Lantus ili ako niste injicirali dovoljno inzulina, razina šećera u krvi može postati previsoka (hiperglikemija).
You should contact your doctor for advice on driving if: - you have frequent episodes of hypoglycaemia, - the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent.
- ako imate česte epizode hipoglikemije, - ako su Vam prvi upozoravajući znakovi hipoglikemije slabije izraženi ili izostaju.
Packs of 1, 2, 5 and 10 vials
Pakiranja od 1, 2, 5 i 10 bočica.
LABEL (10 ml vial)
NALJEPNICA (bočica od 10 ml)
Unopened cartridges:
Neotvorene brizgalice:
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
U bolesnika s oštećenjem funkcije bubrega potrebe za inzulinom mogu biti smanjene zbog usporenog metabolizma inzulina.
A. Put the outer needle cap back on the needle, and use it to unscrew the needle from the pen.
Vratite vanjski zatvarač igle na iglu i pomoću njega odvijte iglu s brizgalice.
Common reported side effects (may affect up to 1 in 10 people)
Često prijavljene nuspojave (mogu se javiti u manje od 1 na 10 osoba)
It may harm them,
ugljikohidrati),
The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group.
1,05 u skupini koja je primala inzulin glargin i 0,30 u skupini koja je primala standardno liječenje, dok je stopa potvrđene hipoglikemije koja se nije smatrala teškom iznosila 7,71 u skupini koja je primala inzulin glargin te 2,44 u skupini koja je primala standardno liječenje.
LABEL (5 ml vial)
NALJEPNICA (bočica od 5 ml)
EU/1/00/134/001 1 vial of 5 ml EU/1/00/134/002 2 vials of 5 ml EU/1/00/134/003 5 vials of 5 ml EU/1/00/134/004 10 vials of 5 ml
EU/1/00/134/002 2 bočice od 5 ml EU/1/00/134/003 5 bočica od 5 ml EU/1/00/134/004 10 bočica od 5 ml
Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography.
godišnjem otvorenom kliničkom ispitivanju kontroliranom NPH inzulinom (NPH primijenjen dvaput na dan) na 1024 bolesnika sa šećernom bolešću tipa 2, u kojih je progresija retinopatije za više od 3
Once in use, the 5 ml vial may be stored for a maximum of 4 weeks in the outer carton not above 25°C and away from direct heat or direct light.
Kad je u uporabi, bočica od 5 ml može se čuvati najdulje 4 tjedna u vanjskom pakiranju na temperaturi do 25°C, zaštićena od izvora topline i izravne svjetlosti.
- The other ingredients are: zinc chloride, metacresol, glycerol, sodium hydroxide (see section 2 “Important information about some of the ingredients of Lantus”) and hydrochloric acid (for pH adjustment), polysorbate 20 (10 ml vial only) and water for injections.
- Drugi sastojci su: cinkov klorid, metakrezol, glicerol, natrijev hidroksid (vidjeti dio 2 "Važne informacije o nekim sastojcima lijeka Lantus") i kloridna kiselina (za prilagodbu pH), polisorbat 20 (samo bočica od 10 ml) i voda za injekcije.
Examples include: - you inject too much insulin, - you miss meals or delay them, - you do not eat enough, or eat food containing less carbohydrate than normal (sugar and substances similar to sugar are called carbohydrates; however, artificial sweeteners are NOT
- ako preskočite ili odgodite obrok, - ako ne jedete dovoljno ili jedete hranu koja sadrži manje ugljikohidrata nego što je uobičajeno
Use only clear and colourless solutions.
Primijeniti samo bistru i bezbojnu otopinu.
Unopened:
Neotvoreni ulošci:
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
Tvari koje mogu pojačati učinak na snižavanje razine glukoze u krvi i povećati sklonost hipoglikemiji obuhvaćaju oralne antidijabetike, inhibitore angiotenzin konvertirajućeg enzima (ACE), dizopiramid,
If you have injected too much Lantus, your blood sugar level may become too low (hypoglycaemia).
Ako ste injicirali previše lijeka Lantus, razina šećera u krvi može postati preniska (hipoglikemija).
If administration by syringe is necessary, a vial should be used (see section 4.2).
. Ako je potrebna primjena pomoću štrcaljke, potrebno je koristiti bočicu (vidjeti dio 4.2).
Discard your used SoloStar as required by your local authorities.
Upotrijebljenu SoloStar brizgalicu potrebno je zbrinuti sukladno lokalnim propisima.
- The other ingredients are: zinc chloride, metacresol, glycerol, sodium hydroxide (see section 2 “Important information about some of the ingredients of Lantus”) and hydrochloric acid (for pH adjustment) and water for injections.
- Drugi sastojci su: cinkov klorid, metakrezol, glicerol, natrijev hidroksid (vidjeti dio 2 "Važne informacije o nekim sastojcima lijeka Lantus") i kloridna kiselina (za prilagodbu pH) i voda za injekcije.
Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening.
Takve reakcije na inzulin (uključujući inzulin glargin) ili na pomoćne tvari mogu, primjerice, biti povezane s generaliziranim kožnim reakcijama,
Each ml of the solution contains 100 units of insulin glargine (equivalent to 3.64 mg).
Jedan ml otopine sadrži 100 jedinica inzulina glargina (što odgovara 3,64 mg).
Each pen contains 3 ml of solution for injection (equivalent to 300 units).
Jedan uložak sadrži 3 ml otopine za injekciju (što odgovara 300 jedinica).
If you have any questions about SoloStar or about diabetes, ask your doctor, pharmacist or nurse or call the local representative number on the front of this leaflet.
ljekarniku ili medicinskoj sestri ili nazovite broj lokalnog predstavnika naveden na prednjoj strani ove upute.
The pen containing the cartridge must not be stored in the refrigerator.
Brizgalica koja sadrži uložak ne smije se odlagati u hladnjak.
Each cartridge or pen contains 3 ml of solution for injection, equivalent to 300 units.
Jedan uložak ili jedna napunjena brizgalica sadrže 3 ml otopine za injekciju, što odgovara 300 jedinica.
• Skin and allergic reactions at the injection site The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation.
Znakovi mogu uključivati crvenilo, neuobičajeno jaku bol prilikom injiciranja, svrbež, osip, oticanje ili upalu.
Method of administration Lantus is administered subcutaneously.
Lantus se primjenjuje supkutano.
Unopened vials, unopened cartridges, not in-use SoloStar pens Store in a refrigerator (2°C-8°C).
Neotvorene bočice Čuvati u hladnjaku (2°C-8°C).
Do not use this medicine after the expiry date which is stated on the carton and on the label of the vial after “EXP”.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i naljepnici na ulošku iza "EXP".
Each cartridge contains 3 ml of solution for injection (equivalent to 300 units).
Jedna brizgalica sadrži 3 ml otopine za injekciju (što odgovara 300 jedinica).
Musculoskeletal and connective tissue disorders
Poremećaji mišićno koštanog sustava i vezivnog tkiva mialgija
Once in use, the 10 ml vial may be stored for a maximum of 4 weeks in the outer carton not above 30°C and away from direct heat or direct light.
Kad je u uporabi, bočica od 10 ml može se čuvati najdulje 4 tjedna u vanjskom pakiranju na temperaturi do 30°C, zaštićena od izvora topline i izravne svjetlosti.
Clear colourless solution.
Bistra, bezbojna otopina.
Type 1 colourless glass vial with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene) containing 5 ml of solution.
Bočica od bezbojnog stakla tipa 1 sa zatvaračem s rubnikom (aluminij), čepom (klorobutilna guma (tip 1)) i zatvaračem koji se otkida (polipropilen) sadrži 5 ml otopine.
Type 1 colourless glass vial with a flanged cap (aluminium), a stopper (type 1, laminate of polyisoprene and bromobutyl rubber) and a tear-off cap (polypropylene) containing 10 ml of solution.
Bočica od bezbojnog stakla tipa 1 sa zatvaračem s rubnikom (aluminij), čepom (tip 1, poliizoprenski laminat i bromobutilna guma) i zatvaračem koji se otkida (polipropilen) sadrži 10 ml otopine.
Handling of the SoloStar pre-filled pen
Rukovanje napunjenom brizgalicom SoloStar